HIQA publishes quarterly bulletin summarizing HTA and evidence synthesis work for April–June 2026 (hiqa.ie)

• HIQA published draft HTA on COVID-19 vaccination policy for 2027–2028, with public consultation open until August 2026; twice-yearly vaccination for over-80s estimated to cost €112 million over five years.
• Minister for Health approved extension of BowelScreen to ages 50–54 based on HIQA HTA; expansion to require phased investment and increased capacity.
• Teledermatology HTA estimated €2.7 million additional cost over 10 years but would allow management of 270,000 more patients, improving referral pathways.
• No serious safety concerns found in 30-year use of vesicostomy buttons in children; high patient and carer satisfaction.
• Newborn screening protocol for congenital adrenal hyperplasia under development; male infants currently at higher risk of delayed diagnosis.

"HIQA's quarterly bulletin for April–June 2026 details multiple health technology assessments (HTAs) and evidence reviews in Ireland. Key items include a public consultation on COVID-19 vaccination policy for 2027–2028, extending BowelScreen to ages 50–54 (approved by the Minister), teledermatology to manage referrals, and a protocol for newborn screening for congenital adrenal hyperplasia. Other work includes a pediatric early warning system, asthma education, vesicostomy buttons, RSV immunization, alcohol guidelines, and services for severe neurological impairment. The bulletin also reports on conferences, patient involvement, and academic publications."